NO951861D0 - ECK-reseptorligander - Google Patents

ECK-reseptorligander

Info

Publication number
NO951861D0
NO951861D0 NO951861A NO951861A NO951861D0 NO 951861 D0 NO951861 D0 NO 951861D0 NO 951861 A NO951861 A NO 951861A NO 951861 A NO951861 A NO 951861A NO 951861 D0 NO951861 D0 NO 951861D0
Authority
NO
Norway
Prior art keywords
eck receptor
eck
disclosed
receptor
receptor ligands
Prior art date
Application number
NO951861A
Other languages
English (en)
Other versions
NO951861L (no
Inventor
Timothy D Bartley
William J Boyle
Gary M Fox
Andrew A Welcher
Vann P Parker
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO951861D0 publication Critical patent/NO951861D0/no
Publication of NO951861L publication Critical patent/NO951861L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
NO951861A 1992-11-13 1995-05-11 ECK-reseptorligander NO951861L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97770892A 1992-11-13 1992-11-13
US14561693A 1993-11-09 1993-11-09
PCT/US1993/010879 WO1994011020A1 (en) 1992-11-13 1993-11-12 Eck receptor ligands

Publications (2)

Publication Number Publication Date
NO951861D0 true NO951861D0 (no) 1995-05-11
NO951861L NO951861L (no) 1995-07-11

Family

ID=26843152

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951861A NO951861L (no) 1992-11-13 1995-05-11 ECK-reseptorligander

Country Status (14)

Country Link
US (2) US5650504A (no)
EP (1) EP0597503B1 (no)
JP (1) JPH08505765A (no)
CN (1) CN1094446A (no)
AT (1) ATE172246T1 (no)
AU (1) AU685765B2 (no)
CA (1) CA2149333C (no)
DE (1) DE69321555T2 (no)
DK (1) DK0597503T3 (no)
ES (1) ES2121915T3 (no)
FI (1) FI952328A (no)
IL (1) IL107599A0 (no)
NO (1) NO951861L (no)
WO (1) WO1994011020A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504667A (ja) * 1990-10-16 1994-06-02 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 炎症性反応生起に関連するサイトカイン−誘起マーカー
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
ATE350386T1 (de) * 1992-11-13 2007-01-15 Immunex Corp Elk ligand, ein cytokin
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
EP0758381B2 (en) * 1994-04-04 2006-11-15 Regeneron Pharmaceuticals, Inc. Biologically active eph family ligands
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
EP0787148B1 (en) * 1994-10-27 2004-04-07 Genentech, Inc. Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor
US5798448A (en) 1994-10-27 1998-08-25 Genentech, Inc. AL-1 neurotrophic factor antibodies
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US6100346A (en) * 1995-03-06 2000-08-08 Ethicon, Inc. Copolymers of polyoxaamides
US6610296B2 (en) 1995-10-26 2003-08-26 Genentech, Inc. Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
DE69924009T2 (de) 1998-12-23 2006-04-13 Regeneron Pharmaceuticals, Inc. Methode zur verstärkung der biologischen aktivität von liganden
US6248725B1 (en) * 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
EP1820860A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2002086460A1 (en) * 2001-04-20 2002-10-31 Consensus Pharmaceuticals, Inc. Methods for identifying ligands of g-protein-coupled receptors
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
JP4585968B2 (ja) * 2002-05-10 2010-11-24 パーデュー・リサーチ・ファウンデーション ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
ES2373715T3 (es) * 2002-05-10 2012-02-08 Medimmune, Llc Anticuerpos monoclonales frente a epha2 y procedimientos de uso de los mismos.
JP2006507256A (ja) 2002-09-24 2006-03-02 ザ バーナム インスティチュート Ｅｐｈ受容体活性を調節する新規薬剤
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1606305A4 (en) 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
AU2004230539A1 (en) * 2003-04-11 2004-10-28 Medimmune, Llc EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
US20050059592A1 (en) * 2003-04-11 2005-03-17 Kiener Peter A. EphA2 and hyperproliferative cell disorders
EP2266628A3 (en) * 2003-05-13 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Method of determining the susceptibility to bone meatastases by EPhA2 expression
EP1730196B1 (en) 2004-03-12 2010-12-22 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
CN102718867A (zh) 2004-03-12 2012-10-10 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
DE602006017964D1 (de) 2005-01-27 2010-12-16 Burnham Inst La Jolla Ephb-rezeptorbindende peptide
AU2008287427B2 (en) 2007-08-13 2014-10-09 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to EphB4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9001052A (nl) * 1990-05-02 1991-12-02 Tno Werkwijze voor het bepalen van een specifiek ligand in een vloeibaar monster met behulp van een evanescent veld, alsook een daarvoor geschikt onderdeel van de benodigde meetinrichting.
JPH06504667A (ja) * 1990-10-16 1994-06-02 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 炎症性反応生起に関連するサイトカイン−誘起マーカー

Also Published As

Publication number Publication date
ES2121915T3 (es) 1998-12-16
EP0597503A3 (en) 1995-05-24
DK0597503T3 (da) 1999-06-23
CA2149333A1 (en) 1994-05-26
WO1994011020A1 (en) 1994-05-26
DE69321555T2 (de) 1999-06-24
ATE172246T1 (de) 1998-10-15
IL107599A0 (en) 1994-02-27
FI952328A (fi) 1995-07-10
US5716934A (en) 1998-02-10
AU5599794A (en) 1994-06-08
DE69321555D1 (de) 1998-11-19
NO951861L (no) 1995-07-11
EP0597503A2 (en) 1994-05-18
FI952328A0 (fi) 1995-05-12
CA2149333C (en) 2002-01-22
AU685765B2 (en) 1998-01-29
EP0597503B1 (en) 1998-10-14
JPH08505765A (ja) 1996-06-25
CN1094446A (zh) 1994-11-02
US5650504A (en) 1997-07-22

Similar Documents

Publication Publication Date Title
DK0597503T3 (da) ECK-receptorligander
WO1996036713A3 (en) Eck receptor ligands
DE68907407D1 (de) Verfahren zur sequenzanalyse von dna.
ATE87655T1 (de) Markierer der t-zelle aktivierung.
NO903059D0 (no) Ligander og reseptorer omfattende nevnte ligander, fremgangsmaate for deres fremstilling og anvendelse.
ATE451390T1 (de) Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys)
DK0662827T3 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
DK446386A (da) Proteinhydrolysater, fremgangsmaader til fremstilling deraf og laegemidler, der indeholder disse hydrolysater
WO1994023030A3 (en) Methods and materials relating to the functional domains of dna binding proteins
DK165199C (da) Aktivatorpraeparat, fremgangsmaade til kvantitativ bestemmelse af protein c under anvendelse af praeparatet, antithrombotisk laegemiddel indeholdende praeparatet og fremgangsmaade til udvinding af aktiveret protein c under anvendelse af praeparatet
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ATE191568T1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
DE69637941D1 (de) Modifizierte hämoglobinähnliche verbindungen und verfahren zu deren reinigung
DK493988D0 (da) 4-oxo-3-quinolincarboxylsyrer, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse forbindelser
AU7160887A (en) Antiparatypical antibodies, their use for detecting and treating auto-immune diseases
DE3889232D1 (de) Verfahren zum quantitativen Nachweis von Sauerstoff.
NO872223D0 (no) Bakteriociner og preparater inneholdende disse for anti-virus behandling.
DE3688451D1 (de) Konjugate von vinblastin und seine derivate, verfahren zur herstellung derselben und diese konjugate enthaltende pharmazeutische zusammensetzungen.
DK623089A (da) Trombolytiske proteiner, fremgangsmaade til fremstilling deraf og praeparater indeholdende disse forbindelser
DK276690A (da) Selenophenderivater, fremgangsmaade til deres fremstilling og terapeutiske praeparater indeholdende disse
DK362288A (da) Homocyclostatin- og cyclostatinholdige peptider og farmaceutiske praeparater indeholdende disse
ATE91156T1 (de) Verfahren zur sequenzanalyse von dna.
DE3674802D1 (de) Verfahren zum nachweis von proteinen und viren.
ATE93969T1 (de) Verfahren zum nachweis von fremdstoffgehalten in gasen.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application